Phaseline

Targets › TRAIL-R2

TRAIL-R2: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 1; Oncology; next expected readout Jan 2029.

Open in Phaseline: the race on TRAIL-R2, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Baylor College of MedicineHTR2 T Cells
TRAIL-R2 and HER2 bi-specific chimeric antigen receptor (CAR) T cells
TRAIL-R2, ERBB2Phase 1Breast CancerJan 2029

Conditions

Breast Cancer (1)

Modalities

other (1)

Companies

Baylor College of Medicine (1)

Related targets

ERBB2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.